Brain cancer drug penetration study halted early
NCT ID NCT04424966
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This early-stage study aimed to see how much of the drug infigratinib gets into brain tumors in people with recurrent high-grade glioma (a fast-growing brain cancer). Only 7 participants were enrolled before the study was stopped. Researchers measured drug levels in tumor tissue, blood, and spinal fluid after a single dose given before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chandler Regional Medical Center
Chandler, Arizona, 85224, United States
-
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona, 85251, United States
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.